CoChat

Strategies for Glycoengineering Therapeutic Proteins

Open access
Dammen-Brower, Kris, Epler, Paige, Zhu, Stanley, Bernstein, Zachary J., Stabach, Paul R., Braddock, Demetrios T., Spangler, Jamie B., Yarema, Kevin J. · 2022 · Frontiers in Chemistry
Cited by 62

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Almost all therapeutic proteins are glycosylated, with the carbohydrate component playing a long-established, substantial role in the safety and pharmacokinetic properties of this dominant category of drugs. In the past few years and moving forward, glycosylation is increasingly being implicated in the pharmacodynamics and therapeutic efficacy of therapeutic proteins. This article provides illustrative examples of drugs that have already been improved through glycoengineering including cytokines exemplified by erythropoietin (EPO), enzymes (ectonucleotide pyrophosphatase 1, ENPP1), and IgG antibodies (e.g., afucosylated Gazyva®, Poteligeo®, Fasenra™, and Uplizna®). In the future, the deliberate modification of therapeutic protein glycosylation will become more prevalent as glycoengineering strategies, including sophisticated computer-aided tools for “building in” glycans sites, acceptance of a broad range of production systems with various glycosylation capabilities, and supplementation methods for introducing non-natural metabolites into glycosylation pathways further develop and become more accessible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fchem.2022.863118

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 233

  1. Abu-Qarn, 2008, Not just for Eukarya Anymore: Protein Glycosylation in Bacteria and Archaea, Curr. Opin. Struct. Biol., 18, 544, 10.1016/j.sbi.2008.06.010 · DOI · Paper page
  2. Ackerman, 2013, Natural Variation in Fc Glycosylation of HIV-specific Antibodies Impacts Antiviral Activity, J. Clin. Invest., 123, 2183, 10.1172/jci65708 · DOI · Paper page
  3. Agatemor, 2019, Exploiting Metabolic Glycoengineering to advance Healthcare, Nat. Rev. Chem., 3, 605, 10.1038/s41570-019-0126-y · DOI · Paper page
  4. Agatemor, 2021, Imaging Glycans with Metabolic Glycoengineering, 253
  5. Aich, 2008, Regioisomeric SCFA Attachment to Hexosamines Separates Metabolic Flux from Cytotoxicity and MUC1 Suppression, ACS Chem. Biol., 3, 230, 10.1021/cb7002708 · DOI
  6. Ailor, 2000, N-glycan Patterns of Human Transferrin Produced in Trichoplusia Ni Insect Cells: Effects of Mammalian Galactosyltransferase, Glycobiology, 10, 837, 10.1093/glycob/10.8.837 · DOI
  7. Albright, 2015, ENPP1-Fc Prevents Mortality and Vascular Calcifications in Rodent Model of Generalized Arterial Calcification of Infancy, Nat. Commun., 6, 10006, 10.1038/ncomms10006 · DOI · Paper page
  8. Almaraz, 2012, Metabolic Oligosaccharide Engineering with N-Acyl Functionalized ManNAc Analogs: Cytotoxicity, Metabolic Flux, and Glycan-Display Considerations, Biotechnol. Bioeng., 109, 992, 10.1002/bit.24363 · DOI
  9. Alter, 2018, Antibody Glycosylation in Inflammation, Disease and Vaccination, Semin. Immunol., 39, 102, 10.1016/j.smim.2018.05.003 · DOI · Paper page
  10. Alves, 2016, Human Carboxylesterase 2: Studies on the Role of Glycosylation for Enzymatic Activity, Biochem. Biophys. Rep., 5, 105, 10.1016/j.bbrep.2015.11.018 · DOI
  11. Arena de Souza, 2015, Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1, PLoS One, 10, e0143919, 10.1371/journal.pone.0143919 · DOI
  12. Ayoub, 2013, Correct Primary Structure Assessment and Extensive Glyco-Profiling of Cetuximab by a Combination of Intact, Middle-Up, Middle-Down and Bottom-Up ESI and MALDI Mass Spectrometry Techniques, mAbs, 5, 699, 10.4161/mabs.25423 · DOI · Paper page
  13. Barahona Afonso, 2016, The Production Processes and Biological Effects of Intravenous Immunoglobulin, Biomolecules, 6, 15, 10.3390/biom6010015 · DOI
  14. Bartsch, 2018, Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis, Front. Immunol., 9, 1183, 10.3389/fimmu.2018.01183 · DOI
  15. Baskin, 2007, Copper-free Click Chemistry for Dynamic In Vivo Imaging, Proc. Natl. Acad. Sci. U.S.A., 104, 16793, 10.1073/pnas.0707090104 · DOI · Paper page
  16. Beck, 2010, GlycoFi's Technology to Control the Glycosylation of Recombinant Therapeutic Proteins, Expert Opin. Drug Discov., 5, 95, 10.1517/17460440903413504 · DOI · Paper page
  17. Bencharit, 2003, Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine, Chem. Biol., 10, 341, 10.1016/s1074-5521(03)00071-1 · DOI · Paper page
  18. Boekhout, 2011, Trastuzumab, Tratuzumab. Oncologist., 16, 800, 10.1634/theoncologist.2010-0035 · DOI
  19. Bork, 2009, Increasing the Sialylation of Therapeutic Glycoproteins: the Potential of the Sialic Acid Biosynthetic Pathway, J. Pharm. Sci., 98, 3499, 10.1002/jps.21684 · DOI · Paper page
  20. Boune, 2020, Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations, Antibodies, 9, 22, 10.3390/antib9020022 · DOI
  21. Boyce, 2011, Metabolic Cross-Talk Allows Labeling of O-Linked β- N -Acetylglucosamine-Modified Proteins via the N -acetylgalactosamine Salvage Pathway, Proc. Natl. Acad. Sci. U.S.A., 108, 3141, 10.1073/pnas.1010045108 · DOI · Paper page
  22. Breitfeld, 1984, Influence of the N-Linked Oligosaccharides on the Biosynthesis, Intracellular Routing, and Function of the Human Asialoglycoprotein Receptor, J. Biol. Chem., 259, 10414, 10.1016/s0021-9258(18)90980-4 · DOI · Paper page
  23. Brumshtein, 2010, Characterization of Gene-Activated Human Acid- -glucosidase: Crystal Structure, Glycan Composition, and Internalization into Macrophages, Glycobiology, 20, 24, 10.1093/glycob/cwp138 · DOI
  24. Buettner, 2018, Improving Immunotherapy through Glycodesign, Front. Immunol., 9, 2485, 10.3389/fimmu.2018.02485 · DOI
  25. Burgdorf, 2006, The Mannose Receptor Mediates Uptake of Soluble but Not of Cell-Associated Antigen for Cross-Presentation, J. Immunol., 176, 6770, 10.4049/jimmunol.176.11.6770 · DOI · Paper page
  26. Burkhart, 2006, Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases, J. Med. Chem., 49, 7002, 10.1021/jm060597e · doi:10.1021/jm060597e
  27. Burnett, 2020, Therapeutic Recombinant Protein Production in Plants: Challenges and Opportunities, Plants People Planet., 2, 121, 10.1002/ppp3.10073 · DOI · Paper page
  28. Casalino, 2020, Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein, ACS Cent. Sci., 6, 1722, 10.1021/acscentsci.0c01056 · DOI · Paper page
  29. Castilho, 2012, Glyco-engineering in Plants to Produce Human-like N-Glycan Structures, Biotechnol. J., 7, 1088, 10.1002/biot.201200032 · DOI
  30. Chitlaru, 1998, Modulation of Circulatory Residence of Recombinant Acetylcholinesterase through Biochemical or Genetic Manipulation of Sialylation Levels, Biochem. J, 336, 647, 10.1042/bj3360647 · DOI
  31. Cobb, 2020, The History of IgG Glycosylation and where We Are Now, Glycobiology, 30, 202, 10.1093/glycob/cwz065 · DOI · Paper page
  32. Contreras-Gómez, 2014, Protein Production Using the Baculovirus-Insect Cell Expression System, Biotechnol. Prog., 30, 1, 10.1002/btpr.1842 · DOI · Paper page
  33. Cowper, 2018, Comprehensive Glycan Analysis of Twelve Recombinant Human Erythropoietin Preparations from Manufacturers in China and Japan, J. Pharm. Biomed. Anal., 153, 214, 10.1016/j.jpba.2018.02.043 · DOI
  34. Cox, 2009, FluBlok, a Next Generation Influenza Vaccine Manufactured in Insect Cells, Biologicals, 37, 182, 10.1016/j.biologicals.2009.02.014 · DOI · Paper page
  35. Cox, 2012, Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective, Dddt, 6, 81, 10.2147/DDDT.S14395 · DOI
  36. Davis, 2014, Naturally Occurring Follicle-Stimulating Hormone Glycosylation Variants, J. Glycomics Lipidomics, 4, e117, 10.4172/2153-0637.1000e117 · doi:10.4172/2153-0637.1000e117
  37. Daya, 2004, Follicle-stimulating Hormone in Clinical Practice, Treatments Endocrinol., 3, 161, 10.2165/00024677-200403030-00004 · DOI
  38. De Wachter, 2018, Engineering of Yeast Glycoprotein Expression, Adv. Biochem. Eng. Biotechnol., 175, 93, 10.1007/10_2018_69 · DOI
  39. Dias, 2021, New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect, Front. Endocrinol., 12, 636038, 10.3389/fendo.2021.636038 · DOI
  40. Ding, 2019, Improving Production of N-Glycosylated Recombinant Proteins by Leaky Escherichia coli, 3 Biotech., 9, 302, 10.1007/s13205-019-1830-5 · doi:10.1007/s13205-019-1830-5
  41. Drake, 2014, Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct In Vivo Efficacy and PK Outcomes, Bioconjug. Chem., 25, 1331, 10.1021/bc500189z · DOI · Paper page
  42. Du, 2021, Glycoengineering Human Neural and Adipose Stem Cells with Novel Thiol-Modified N-Acetylmannosamine (ManNAc) Analogs, Cells, 10, 377377, 10.3390/cells10020377 · DOI
  43. Du, 2022, Glycoengineering Human Neural Stem Cells (hNSCs) for Adhesion Improvement Using a Novel Thiol-Modified N-Acetylmannosamine (ManNAc) Analog, Mater. Sci. Eng. C, 2022, 112675, 10.1016/j.msec.2022.112675 · DOI
  44. Du, 2009, Metabolic Glycoengineering: Sialic Acid and beyond, Glycobiology, 19, 1382, 10.1093/glycob/cwp115 · DOI · Paper page
  45. Dwek, 2002, Introduction: GlycobiologyUnderstanding the Language and Meaning of Carbohydrates, Chem. Rev., 102, 283, 10.1021/cr010385j · doi:10.1021/cr010385j
  46. Dwek, 1996, Glycobiology: Toward Understanding the Function of Sugars, Chem. Rev., 96, 683, 10.1021/10.1021/cr940283b · doi:10.1021/10.1021/cr940283b
  47. Egrie, 2002, Development and Characterization of Darbepoetin Alfa, Oncology (Williston Park), 16, 13
  48. Ellies, 2002, Sialyltransferase ST3Gal-IV Operates as a Dominant Modifier of Hemostasis by Concealing Asialoglycoprotein Receptor Ligands, Proc. Natl. Acad. Sci. U.S.A., 99, 10042, 10.1073/pnas.142005099 · DOI · Paper page
  49. Elliot, 2000, Rational Design of Novel Erythropoiesis Stimulating Protein (AranespTM): a Super-sialylated Molecule with Increased Biological Activity, Blood, 96
  50. Elliott, 2008, Erythropoietins: A Common Mechanism of Action, Exp. Hematol., 36, 1573, 10.1016/j.exphem.2008.08.003 · DOI · Paper page
  51. Feinberg, 2021, Structural Analysis of Carbohydrate Binding by the Macrophage Mannose Receptor CD206, J. Biol. Chem., 296, 100368, 10.1016/j.jbc.2021.100368 · DOI
  52. Ferreira, 2021, Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies, J. Bone Miner. Res., 36, 2193, 10.1002/jbmr.4418 · DOI
  53. Fischer, 2018, Glyco-engineering of Plant-Based Expression Systems, Adv. Biochem. Eng. Biotechnol., 175, 137, 10.1007/10_2018_76 · DOI
  54. Fleming, 2005, Structural Insights into Drug Processing by Human Carboxylesterase 1: Tamoxifen, Mevastatin, and Inhibition by Benzil, J. Mol. Biol., 352, 165, 10.1016/j.jmb.2005.07.016 · DOI
  55. Fleming, 2007, Crystal Structures of Human Carboxylesterase 1 in Covalent Complexes with the Chemical Warfare Agents Soman and Tabun,, Biochemistry, 46, 5063, 10.1021/bi700246n · DOI
  56. Fox, 2021, A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis, Mult. Scler., 27, 420, 10.1177/1352458520918375 · DOI
  57. Fox, 2012, First Plant-Made Biologic Approved, Nat. Biotechnol., 30, 472, 10.1038/nbt0612-472 · DOI
  58. Friedman, 1999, A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived β-Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease, Blood, 93, 2807, 10.1182/blood.v93.9.2807.409k08_2807_2816 · doi:10.1182/blood.v93.9.2807.409k08_2807_2816
  59. Friedman, 2008, A Southern Mystery., 26526
  60. Fukami, 2012, The Emerging Role of Human Esterases, Drug Metab. Pharmacokinet., 27, 466, 10.2133/dmpk.dmpk-12-rv-042 · DOI · Paper page
  61. Gazi, 2009, Influence of the Mannose Receptor in Host Immune Responses, Immunobiology, 214, 554, 10.1016/j.imbio.2008.11.004 · DOI · Paper page
  62. Geisler, 2015, An Overview and History of Glyco-Engineering in Insect Expression Systems, 131
  63. Giddens, 2018, Site-selective Chemoenzymatic Glycoengineering of Fab and Fc Glycans of a Therapeutic Antibody, Proc. Natl. Acad. Sci. U.S.A., 115, 12023, 10.1073/pnas.1812833115 · DOI
  64. Go, 2017, Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers, J. Virol., 91, e02428-02416, 10.1128/jvi.02428-16 · DOI
  65. Golay, 2013, Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis through CD16B More Efficiently Than Rituximab, Blood, 122, 3482, 10.1182/blood-2013-05-504043 · DOI · Paper page
  66. Gong, 2021, The Glycosylation in SARS-CoV-2 and its Receptor ACE2, Signal. Transduct. Target. Ther., 6, 396, 10.1038/s41392-021-00809-8 · DOI · Paper page
  67. Greig, 2002, Butyrylcholinesterase: an Important New Target in Alzheimer's Disease Therapy, Int. Psychogeriatr, 14, 77, 10.1017/s1041610203008676 · DOI · Paper page
  68. Grimsey, 2020, The Effect of Lipidation and Glycosylation on Short Cationic Antimicrobial Peptides, Biochim. Biophys. Acta Biomem., 1862, 183195, 10.1016/j.bbamem.2020.183195 · DOI
  69. Gross, 1988, Enzymatic Introduction of a Fluorescent Sialic Acid into Oligosaccharide Chains of Glycoproteins, Eur. J. Biochem., 177, 583, 10.1111/j.1432-1033.1988.tb14410.x · doi:10.1111/j.1432-1033.1988.tb14410.x
  70. Gross, 1995, Enzymatic Transfer of Sialic Acids Modified at C-5 Employing Four Different Sialyltransferases, Glycoconj. J., 12, 739, 10.1007/BF00731233 · doi:10.1007/bf00731233
  71. Gross, 1989, Transfer of Synthetic Sialic Acid Analogues to N- and O-Linked Glycoprotein Glycans Using Four Different Mammalian Sialyltransferases, Biochemistry, 28, 7386, 10.1021/bi00444a036 · doi:10.1021/bi00444a036
  72. Guan, 2018, Chemically Precise Glycoengineering Improves Human Insulin, ACS Chem. Biol., 13, 73, 10.1021/acschembio.7b00794 · DOI
  73. Gupta, 2002, Prediction of Glycosylation across the Human Proteome and the Correlation to Protein Function, Pac. Symp. Biocomputing, 7, 310
  74. Hamilton, 2015, Progress in Yeast Glycoengineering, 73, 10.1007/978-1-4939-2760-9_6 · DOI
  75. Heß, 2019, Glycosylation of HIV Env Inpacts IgG Subtype Responses to Vaccination, Viruses, 11, 153, 10.3390/v11020153 · DOI
  76. Higashiyama, 2018, Chemo-enzymatic Synthesis of the Glucagon Containing N-Linked Oligosaccharide and its Characterization, Carbohydr. Res., 455, 92, 10.1016/j.carres.2017.11.007 · doi:10.1016/j.carres.2017.11.007
  77. Hokke, 1990, Sialylated Carbohydrate Chains of Recombinant Human Glycoproteins Expressed in Chinese Hamster Ovary Cells Contain Traces of N-Glycolylneuraminic Acid, FEBS Lett., 275, 9, 10.1016/0014-5793(90)81427-P · DOI · Paper page
  78. Hollister, 1988, Stable Expression of Mammalian B1,4-Galactosyltransferase Extends the N-Glycosylation Pathway in Insect Cells, Glycobiology, 8, 473, 10.1093/glycob/8.5.473 · DOI
  79. Hong, 2010, Labeling Live Cells by Copper-Datalyzed Alkyne-Azide Click Chemistry, Bioconjug. Chem., 21, 1912, 10.1021/bc100272z · DOI · Paper page
  80. Hurjak, 2020, N-glycosylation of Blood Coagulation Factor XIII Subunit B and its Functional Consequence, J. Thromb. Haemost., 18, 1302, 10.1111/jth.14792 · doi:10.1111/jth.14792
  81. Ichikawa, 2018, Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-like Peptide-1, ACS Omega, 3, 5346, 10.1021/acsomega.8b00467 · DOI
  82. Irvine, 2020, Understanding the Role of Antibody Glycosylation through the Lens of Severe Viral and Bacterial Diseases, Glycobiology, 30, 241, 10.1093/glycob/cwaa018 · DOI
  83. Jain, 2012, A Review of Glycosylated Carriers for Drug Delivery, Biomaterials, 33, 4166, 10.1016/j.biomaterials.2012.02.033 · DOI · Paper page
  84. Janin-Bussat, 2013, Cetuximab Fab and Fc N-Glycan Fast Characterization Using IdeS Digestion and Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry, Methods Mol. Biol., 988, 93, 10.1007/978-1-62703-327-5_7 · DOI
  85. Ji, 2017, New Insights into Influenza A Specificity: an Evolution of Paradigms, Curr. Opin. Struct. Biol., 44, 219, 10.1016/j.sbi.2017.06.001 · DOI
  86. Johnson, 2013, The Regulatory Power of Glycans and Their Binding Partners in Immunity, Trends Immunol., 34, 290, 10.1016/j.it.2013.01.006 · DOI · Paper page
  87. Jones, 2016, B-cell–independent Sialylation of IgG, Proc. Natl. Acad. Sci. U. S. A., 11, 7207, 10.1073/pnas.1523968113 · DOI
  88. Jones, 2004, Characterization of the Cellular Uptake and Metabolic Conversion of Acetylated N-Acetylmannosamine (ManNAc) Analogues to Sialic Acids, Biotechnol. Bioeng., 85, 394, 10.1002/bit.10901 · doi:10.1002/bit.10901
  89. Joshi, 2001, Production of a Sialylated N-Linked Glycoprotein in Insect Cells, Biotechnol. Prog., 17, 822, 10.1021/bp010071h · doi:10.1021/bp010071h
  90. Jourdian, 1971, The Sialic Acids. XI. A Periodate-Resorcinol Method for the Quantitative Estimation of Free Sialic Acids and Their Glycosides, J. Biol. Chem., 246, 430, 10.1016/s0021-9258(18)62508-6 · DOI · Paper page
  91. Kamber, 2019, Isomeric Triazines Exhibit Unique Profiles of Bioorthogonal Reactivity, Chem. Sci., 10, 9109, 10.1039/c9sc01427f · doi:10.1039/c9sc01427f
  92. Karki, 2021, Cellular Engineering of Plant Cells for Improved Therapeutic Protein Production, Plant Cell Rep., 40, 1087, 10.1007/s00299-021-02693-6 · DOI
  93. Kayser, Incorporation of N-Acyl-2-Amino-2-Deoxy-Hexoses into Glycosphingolipids of the Pheochromocytoma Cell Line PC 12, FEBS Lett., 301, 137, 10.1016/0014-5793(92)81233-c · doi:10.1016/0014-5793(92)81233-c
  94. Kayser, Biosynthesis of a Nonphysiological Sialic Acid in Different Rat Organs, Using N-Propanoyl-D-Hexosamines as Precursors, J. Biol. Chem., 267, 16934, 10.1016/s0021-9258(18)41874-1 · DOI · Paper page
  95. Keppler, 2001, Biochemical Engineering of the N-Acyl Side Chain of Sialic Acid: Biological Implications, Glycobiology, 11, 11R, 10.1093/glycob/11.2.11R · DOI · Paper page
  96. Kim, 2004, Characterization of the Metabolic Flux and Apoptotic Effects of O-Hydroxyl- and N-Acetylmannosamine (ManNAc) Analogs in Jurkat (Human T-Lymphoma-Derived) Cells, J. Biol. Chem., 279, 18342, 10.1074/jbc.M400205200 · DOI
  97. Kim, 2002, Expression of a Functional Drosophila melanogaster N-Acetylneuraminic Acid (Neu5Ac) Phosphate Synthase Gene: Evidence for Endogneous Sialic Acid Biosynthetic Ability in Insects, Glycobiology, 12, 73, 10.1093/glycob/12.2.73 · DOI
  98. Kohi, 2016, Hyaluromycin, a Novel Hyaluronidase Inhibitor, Attenuates Pancreatic Cancer Cell Migration and Proliferation, J. Oncol., 2016, 9063087, 10.1155/2016/9063087 · DOI
  99. Kolarich, 2008, Glycoproteomic Characterization of Butyrylcholinesterase from Human Plasma, Proteomics, 8, 254, 10.1002/pmic.200700720 · DOI
  100. Kolbeck, 2010, MEDI-563, a Humanized anti-IL-5 Receptor Alpha mAb with Enhanced Antibody-dependent Cell-Mediated Cytotoxicity Function, J. Allergy Clin. Immunol., 125, 1344, 10.1016/j.jaci.2010.04.004 · DOI · Paper page
  101. Kosloski, 2009, Role of Glycosylation in Conformational Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII, AAPS J., 11, 424, 10.1208/s12248-009-9119-y · DOI
  102. Kotsovilis, 2014, Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases, Methods Mol. Biol., 1016, 37, 10.1007/978-1-62703-586-6_3 · DOI
  103. Kroetz, 1993, Glycosylation-dependent Activity of Baculovirus-Expressed Human Liver Carboxylesterases: cDNA Cloning and Characterization of Two Highly Similar Enzyme Forms, Biochemistry, 32, 11606, 10.1021/bi00094a018 · DOI
  104. Kulagine, 2021, Yeasts as Biopharmaceutical Production Platforms, Front. Fungal Biol., 2, 733492, 10.3389/ffunb.2021.733492 · DOI
  105. Kurusawa, 2020, Chemically Defined, High-Density Insect Cell-Based Expression System for Scalable AAV Vector Production, Mol. Ther. Methods Clin. Dev., 19, 330, 10.1016/j.omtm.2020.09.018 · DOI
  106. Labonte, 2016, Residue-centric Modeling and Design of Saccharide and Glycoconjugate Structures, J. Comput. Chem., 38, 276, 10.1002/jcc.24679 · DOI · Paper page
  107. Lajoie, 2007, Plasma Membrane Domain Organization Regulates EGFR Signaling in Tumor Cells, J. Cell Biol., 179, 341, 10.1083/jcb.200611106 · DOI · Paper page
  108. Lawrence, 2001, Cloning and Expression of Human Sialic Acid Pathway Genes to Generate CMP-Sialic Acids in Insect Cells, Glycoconj. J., 18, 205, 10.1023/a:1012452705349 · DOI
  109. Lee, 2002, Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis, Science, 295, 1898, 10.1126/science.1069540 · DOI · Paper page
  110. Lemieux, 1999, Exploiting Differences in Sialoside Expression for Selective Targeting of MRI Contrast Reagents, J. Am. Chem. Soc., 121, 4278, 10.1021/ja984228m · doi:10.1021/ja984228m
  111. Li, Sialylated Immunoglobulin G: A Promising Diagnostic and Therapeutic Strategy for Autoimmune Diseases, Theranostics, 11, 5430, 10.7150/thno.53961 · DOI
  112. Li, 2009, Pharmacological Significance of Glycosylation in Therapeutic Proteins, Curr. Opin. Biotechnol., 20, 678, 10.1016/j.copbio.2009.10.009 · DOI · Paper page
  113. Li, Shotgun Scanning Glycomutagenesis: A Simple and Efficient Strategy for Constructing and Characterizing Neoglycoproteins, Proc. Natl. Acad. Sci. U. S. A., 118, e2107440118, 10.1073/pnas.2107440118 · DOI
  114. Li, 2017, Modulating IgG Effector Function by Fc Glycan Engineering, Proc. Natl. Acad. Sci. U. S. A., 114, 3485, 10.1073/pnas.1702173114 · DOI · Paper page
  115. Li, 2014, Preparation of Well-Defined Antibody–Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide–Alkyne Cycloadditions, Angew. Chem. Int. Ed. Eng., 53, 7179, 10.1002/anie.201402606 · DOI · Paper page
  116. Lifely, 1995, Glycosylation and Biological Activity of CAMPATH-1H Expressed in Different Cell Lines and Grown under Different Culture Conditions, Glycobiology, 5, 813, 10.1093/glycob/5.8.813 · DOI · Paper page
  117. Liu, 2018, Glycoengineering of Antibody (Herceptin) through Yeast Expression and In Vitro Enzymatic Glycosylation, Proc. Natl. Acad. Sci. U. S. A., 115, 720, 10.1073/pnas.1718172115 · DOI
  118. Liu, 2018, Pharmacokinetics of Monoclonal Antibodies and Fc-Fusion Proteins, Protein Cell, 9, 15, 10.1007/s13238-017-0408-4 · DOI · Paper page
  119. Liu, 2021, N-glycosylation and Enzymatic Activity of the rHuPH20 Expressed in Chinese Hamster Ovary Cells, Anal. Biochem., 632, 114380, 10.1016/j.ab.2021.114380 · DOI
  120. Loos, 2012, IgG-Fc Glycoengineering in Non-mammalian Expression Hosts, Arch. Biochem. Biophys., 526, 167, 10.1016/j.abb.2012.05.011 · DOI
  121. Lu, 2020, Development of Therapeutic Antibodies for the Treatment of Dieases, J. Biomed. Sci., 27, 1, 10.1186/s12929-019-0592-z · DOI · Paper page
  122. Luo, 2017, Glycoengineering of Pertuzumab and its Impact on the Pharmacokinetic/pharmacodynamic Properties, Sci. Rep., 7, 46347, 10.1038/srep46347 · DOI · Paper page
  123. Ma, Protein Glycoengineering: An Approach for Improving Protein Properties, Front. Chem., 8, 622, 10.3389/fchem.2020.00622 · DOI
  124. Ma, Protein Glycoengineering: An Approach for Improving Protein Properties, Front. Chem., 8, 622, 10.3389/fchem.2020.00622 · DOI
  125. Maack, 1979, Renal Filtration, Transport, and Metabolism of Low-Molecular-Weight Proteins: A Review, Kidney Int., 16, 251, 10.1038/ki.1979.128 · DOI · Paper page
  126. Mabashi-Asazuma, 2014, A Novel Baculovirus for the Production of Nonfucosylated Recombinant Glycoproteins in Insect Cells, Glycobiology, 24, 325, 10.1093/glycob/cwt161 · DOI
  127. Macdougal, 2002, Optimizing the Use of Erythropoietic Agents – Pharmacokinetic and Pharmacodynamic Considerations, Nephrol. Dial. Transpl., 17, 66, 10.1093/ndt/17.suppl_5.66 · DOI · Paper page
  128. Mahal, 1997, Engineering Chemical Reactivity on Cell Surfaces through Oligosaccharide Biosynthesis, Science, 276, 1125, 10.1126/science.276.5315.1125 · DOI · Paper page
  129. Maneval, 2020, Chapter 9 - Pegvorhyaluronidase Alfa: A PEGylated Recombinant Human Hyaluronidase PH20 for the Treatment of Cancers that Accumulate Hyaluronan
  130. Marchal, 2001, Glycoproteins from Insect Cells: Sialylated or Not?, Biol. Chem., 382, 151, 10.1515/BC.2001.023 · DOI · Paper page
  131. Martins, 2016, A Comprehensive Review of the Neonatal Fc Receptor and its Application in Drug Delivery, Pharmacol. Ther., 161, 22, 10.1016/j.pharmthera.2016.03.007 · DOI
  132. Mastrangeli, 2019, Glycoengineered Antibodies: towards the Next-Generation of Immunotherapeutics, Glycobiology, 29, 199, 10.1093/glycob/cwy092 · DOI
  133. Mathew, 2017, Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid, ChemBioChem, 18, 1204, 10.1002/cbic.201600698 · DOI
  134. Mathew, 2016, Metabolic Flux-Driven Sialylation Alters Internalization, Recycling, and Drug Sensitivity of the Epidermal Growth Factor Receptor (EGFR) in SW1990 Pancreatic Cancer Cells, Oncotarget, 7, 66491, 10.18632/oncotarget.11582 · DOI
  135. Mathew, 2012, Extracellular and Intracellular Esterase Processing of SCFA-Hexosamine Analogs: Implications for Metabolic Glycoengineering and Drug Delivery, Bioorg. Med. Chem. Lett., 22, 6929, 10.1016/j.bmcl.2012.09.017 · doi:10.1016/j.bmcl.2012.09.017
  136. Menacho-Melgar, 2020, Improved, Scalable, Two-Stage, Autoinduction of Recombinant Protein Expression in E. coli Using Phosphate Depletion, bioRxiv, 10.10023/bit.27440 · doi:10.10023/bit.27440
  137. Mertz, 2020, Comparison of Three Glycoproteomic Methods for the Analysis of the Secretome of CHO Cells Treated with 1,3,4-O-Bu3ManNAc, Bioengineering, 7, 144, 10.3390/bioengineering7040144 · DOI
  138. Montero-Morales, 2018, Advanced Plant-Based Glycan Engineering, Front. Bioeng. Biotechnol., 6, 81, 10.3389/fbioe.2018.00081 · DOI
  139. Mullard, 2021, FDA Approves 100th Monoclonal Antibody Product, Nat. Rev. Drug Discov., 20, 491, 10.1038/d41573-021-00079-7 · DOI · Paper page
  140. Muthana, 2009, Recent Progress in Chemical and Chemoenzymatic Synthesis of Carbohydrates, Curr. Opin. Chem. Biol., 13, 573, 10.1016/j.cbpa.2009.09.013 · doi:10.1016/j.cbpa.2009.09.013
  141. Nakano, 2009, Capillary Electrophoresis-Electrospray Ionization Mass Spectrometry for Rapid and Sensitive N-Glycan Analysis of Glycoproteins as 9-fluorenylmethyl Derivatives, Glycobiology, 19, 135, 10.1093/glycob/cwn115 · DOI · Paper page
  142. Narimatsu, 2021, Genetic Glycoengineering in Mammalian Cells, J. Biol. Chem., 296, 100448, 10.1016/j.jbc.2021.100448 · DOI
  143. Ning, 2010, Protein Modification by Strain-Promoted Alkyne-Nitrone Cycloaddition, Angew. Chem. Int. Ed. Eng., 49, 3065, 10.1002/anie.201000408 · DOI
  144. Offersen, 2020, HIV Antibody Fc N-Linked Flycosylation Is Associated with Viral Rebound, Cell Rep, 33, 103502, 10.1016/j.celrep.2020.108502 · DOI
  145. Okeley, 2013, Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody−drug Conjugation, Bioconjug. Chem., 24, 1650, 10.1021/bc4002695 · DOI
  146. Olden, 1982, Carbohydrate Moieties of Glycoproteins a Re-evaluation of Their Function, Biochim. Biophys. Acta, 650, 209, 10.1016/0304-4157(82)90017-X · DOI · Paper page
  147. Orlean, 2012, Architecture and Biosynthesis of the Saccharomyces cerevisiae Cell wall, Genetics, 192, 775, 10.1534/genetics.112.144485 · DOI · Paper page
  148. Ovacik, 2018, Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development, Clin. Transl. Sci., 11, 540, 10.1111/cts.12567 · DOI · Paper page
  149. Palmberger, 2011, Insect Cells for Antibody Production: Evaluation of an Efficient Alternative, J. Biotechnol., 153, 160, 10.1016/j.jbiotec.2011.02.009 · DOI
  150. Pandhal, 2010, N-linked Glycoengineering for Human Therapeutic Proteins in Bacteria, Biotechnol. Lett., 32, 1189, 10.1007/s10529-010-0289-6 · DOI
  151. Pereira, 2018, The "Less-Is-More" in Therapeutic Antibodies: Afucosylated Anti-cancer Antibodies with Enhanced Antibody-Depedent Cellular Cytotoxicity, MAbs, 10, 693, 10.1080/19420862.2018.1466767 · DOI · Paper page
  152. Peters, 1976, Reactivity of the Sialic Acid Derivative 5-Acetamido-3,5-Dideoxy-L-Arabino-Heptulosonic Acid in the Resorcinol and Thiobarbituric Acid Assays, Carbohydr. Res., 47, 345, 10.1016/s0008-6215(00)84204-4 · doi:10.1016/s0008-6215(00)84204-4
  153. Pindel, 1997, Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase that Catalyzes the Hydrolysis of Cocaine and Heroin, J. Biol. Chem., 272, 14769, 10.1074/jbc.272.23.14769 · DOI · Paper page
  154. Pratama, 2021, Genetic and Process Engineering Strategies for Enhanced Recombinant N-Glycoprotein Production in Bacteria, Microb. Cell Fact., 20, 198, 10.1186/s12934-021-01689-x · DOI
  155. Prescher, 2003, Probing Azido Sugar Metabolism In Vivo Using the Staudinger Ligation, Glycobiology, 13, 894
  156. Pucić, 2011, High Throughput Isolation and Glycosylation Analysis of IgG-Variability and Heritability of the IgG Glycome in Three Isolated Human Populations, Mol. Cell. Proteomics, 10, M111, 10.1074/mcp.M111.010090 · DOI · Paper page
  157. Qasba, 2015, Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltranserases, Bioconjug. Chem., 26, 2170, 10.1021/acs.bioconjchem.5b00173 · DOI
  158. Qun, 2019, The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins, J. Pharm. Sci., 108, 1366, 10.1016/j.xphs.2018.11.029 · DOI · Paper page
  159. Rosales-Mendoza, 2015, Implications of Plant Glycans in the Development of Innovative Vaccines, Expert Rev. Vaccin., 15, 915, 10.1586/14760584.2016.1155987 · DOI
  160. Roseman, 2000, Molecular Basis of Lutropin Recognition by mannose/GalNAc-4-SO4 Receptor, Proc. Natl. Acad. Sci. U. S. A., 94, 9949, 10.1073/pnas.170184597 · DOI · Paper page
  161. Rup, 2017, Immunogenicity of Glycans on Biotherapeutic Drugs Produced in Plant Expression Systems - the Taliglucerase Alfa story, PLoS One, 12, e0186211, 10.1371/journal.pone.0186211 · DOI
  162. Ryman, 2017, Pharmacokinetics of Monoclonal Antibodies, CPT Pharmacometrics Syst. Pharmacol., 6, 576, 10.1002/psp4.12224 · DOI · Paper page
  163. Saeui, 2020, Cell Line-, Protein-, and Sialoglycosite-specific Control of Flux-Based Sialylation in Human Breast Cells: Implications for Cancer Progression, Front. Chem., 8, 13, 10.3389/fchem.2020.00013 · DOI
  164. Saez-Valero, 2000, Altered Glycosylation of Acetylcholinesterase in Lumbar Cerebrospinal Fluid of Patients with Alzheimer's Disease, J. Neurol. Neurosurg. Psych., 69, 664, 10.1136/jnnp.69.5.664 · DOI
  165. Sampathkumar, 2006, Metabolic Installation of Thiols into Sialic Acid Modulates Adhesion and Stem Cell Biology, Nat. Chem. Biol., 2, 149, 10.1038/nchembio770 · DOI
  166. Samraj, 2015, A Red Meat-Derived Glycan Promotes Inflammation and Cancer Progression, Proc. Natl. Acad. Sci. U. S. A., 112, 542, 10.1073/pnas.1417508112 · DOI · Paper page
  167. Sanchez-Garcia, 2016, Recombinant Pharmaceuticals from Microbial Cells: a 2015 Update, Microb. Cell Fact., 15, 33, 10.1186/s12934-016-0437-3 · DOI · Paper page
  168. Sarkar, 1995, Disaccharide Uptake and Priming in Animal Cells: Inhibition of Sialyl Lewis X by Acetylated Gal β1,4GalNAc B-Onaphthalenemethanol, Proc. Natl. Acad. Sci. U. S. A., 92, 3323, 10.1073/pnas.92.8.3323 · DOI · Paper page
  169. Sato, 1993, Binding, Internalization, and Degradation of Mannose-Terminated Glucocerebrosidase by Macrophages, J. Clin. Invest., 91, 1909, 10.1172/JCI116409 · DOI
  170. Sawa, 2006, Glycoproteomic Probes for Fluorescent Imaging of Fucosylated Glycans In Vivo, Proc. Natl. Acad. Sci. U. S. A., 103, 12371, 10.1073/pnas.0605418103 · DOI · Paper page
  171. Saxon, 2000, Cell Surface Engineering by a Modified Staudinger Reaction, Science, 287, 2007, 10.1126/science.287.5460.2007 · DOI · Paper page
  172. Schillberg, 2019, Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins, Front. Plant Sci., 10, 720, 10.3389/fpls.2019.00720 · DOI · Paper page
  173. Schneider, 2013, Expression of Human Butyrylcholinesterase with an Engineered Glycosylation Profile Resembling the Plasma-Derived Orthologue, Biotechnol. J., 9, 501, 10.1002/biot.201300229 · DOI
  174. Schwartz, 1984, The Hepatic Asialoglycoprotein Receptor, CRC Crit. Rev. Biochem., 16, 207, 10.3109/10409238409108716 · DOI · Paper page
  175. Seabright, 2019, Protein and Glycan Mimicry in HIV Vaccine Design, J. Mol. Biol., 431, 2223, 10.1016/j.jmb.2019.04.016 · DOI
  176. Semerano, 2009, Les anticorps dans les maladies immunes inflammatooires chroniques, Med. Sci. (Paris)., 25, 1108, 10.1051/medsci/200925121108 · doi:10.1051/medsci/200925121108
  177. Senger, 2009, Enhanced Papillomavirus-like Particle Production in Insect Cells, Virology, 388, 344, 10.1016/j.virol.2009.04.004 · DOI
  178. Shaaltiel, 2007, Production of Glucocerebrosidase with Terminal Mannose Glycans for Enzyme Replacement Therapy of Gaucher's Disease Using a Plant Cell System, Plant Biotechnol. J., 5, 579, 10.1111/j.1467-7652.2007.00263.x · DOI · Paper page
  179. Sheikh, 2000, Endo 180, an Endocytic Recycling Glycoportein Related to the Macrophage Mannose Receptor Is Expressed on Fibroblasts, Endothelial Cells and Macrophages and Functions as a Lectin Receptor, J. Cell Sci., 113, 1021, 10.1242/jcs.113.6.1021 · DOI · Paper page
  180. Shi, 2006, Anti-influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel, J. Pharmacol. Exp. Ther., 19, 1477, 10.1124/jpet.106.111807 · DOI
  181. Shuster, 2002, Hyaluronidase Reduces Human Breast Cancer Xenografts in SCID Mice, Int. J. Cancer, 102, 192, 10.1002/ijc.10668 · DOI · Paper page
  182. Singh, 20152015, Impact of Hybrid and Complex N-Glycans on Cell Surface Targeting of the Endogenous Chloride Cotransporter Slc12a2, Int. J. Cell Biol., 505294, 10.1155/2015/505294 · DOI
  183. Singh, 2016, Microbial Enzymes: Industrial Progress in 21st century, 3 Biotech., 6, 174, 10.1007/s13205-016-0485-8 · DOI · Paper page
  184. Song, 2013, Strategic Addition of an N-Linked Glycan to a Monoclonal Antibody Improves its HIV-1–Neutralizing Activity, Nat. Biotechnol., 31, 1047, 10.1038/nbt.2677 · DOI
  185. Stabach, 2021, Improving the Pharmacodynamics and In Vivo Activity of ENPP1-Fc through Protein and Glycosylation Engineering, Clin. Transl. Sci., 14, 362, 10.1111/cts.12887 · DOI
  186. Stanley, 2005, Chinese Hamster Ovary (CHO) Glycosylation Mutants for Glycan Engineering, 371
  187. Stanley, 1996, CHO Cells Provide Access to Novel N-Glycans and Developmentally Regulated Glycosyltransferases, Glycobiology, 6, 696, 10.1093/glycob/6.7.695 · DOI
  188. Steinke, 2015, The Alpha Gal story: Lessons Learned from Connecting the Dots, J. Allergy Clin. Immunol., 135, 589, 10.1016/j.jaci.2014.12.1947 · DOI · Paper page
  189. Sudo, 2014, Different IVIG Glycoforms Affect In Vitro Inhibition of Anti-ganglioside Antibody-Mediated Complement Deposition, PLoS One, 9, e017772, 10.1371/journal.pone.0107772 · DOI
  190. Sukenik, 2018, Transient Recombinant Protein Production in Glycoengineered Nicotiana Benthamiana Cell Suspension Culture, Int. J. Mol. Sci., 19, 1205, 10.3390/ijms19041205 · DOI
  191. Szolnoky, 2001, A Mannose-Binding Receptor Is Expressed on Human Keratinocytes and Mediates Killing of Candida Albicans, J. Investig. Dermatol., 117, P205, 10.1046/j.1523-1747.2001.14071.x · DOI
  192. Szymanski, 2002, Evidence for a System of General Protein Glycosylation in Campylobacter Jejuni, Mol. Microbiol., 32, 1022, 10.1046/j.1365-2958.1999.01415.x · DOI · Paper page
  193. Tang, 2019, Homogeneous Antibody-Drug Conjugates via Glycoengineering, Methods Mol. Biol., 2033, 221, 10.1007/978-1-4939-9654-4_15 · DOI
  194. Tariq, 2018, Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies, Cancer Res., 78, 2787, 10.1158/0008-5472.can-18-0032 · DOI
  195. Tekoah, 2013, Glycosylation and Functionality of Recombinant B-Glycocerebrosidase from Various Production Systems, Biosci. Rep., 33, e00071, 10.1042/BSR20130081 · DOI · Paper page
  196. Tibbitts, 2016, Key Factors Influencing ADME Properties of Therapeutic Proteins: A Need for ADME Characterization in Drug Discovery and Development, MAbs, 8, 229, 10.1080/19420862.2015.1115937 · DOI · Paper page
  197. Tong, 2003, Glycosylation Changes as Markers for the Diagnosis and Treatment of Human Disease, 199
  198. Top, 2019, Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems, Front. Plant Sci., 10, 261, 10.3389/fpls.2019.00261 · DOI
  199. Torres-Pérez, 2020, Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery, Front. Oncol., 10, 605037, 10.3389/fonc.2020.605037 · DOI
  200. Toth, 2014, A New Insect Cell Glycoengineering Approach Provides Baculovirus-Inducible Glycogene Expression and Increases Human-type Glycosylation Efficiency, J. Biotechnol., 19, 10.1016/j.jbiotec.2014.04.011 · DOI

200 of 233 shown

Cited by

See all 62

Metadata

Authors
Dammen-Brower, K., Epler, P., Zhu, S., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J.
Venue
Frontiers in Chemistry
Published
2022-04-13
Volume
10
Pages
863118-863118
ISSN
2296-2646 (ISSN-L)
OpenAlex
W4224022140
Cited by
62
References
27
FWCI
3.66
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strategies for Glycoengineering Therapeutic Proteins. https://app.cochat.ai/papers/10.3389/fchem.2022.863118
The paper
Dammen-Brower, K., Epler, P., Zhu, S., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J. (2022). Strategies for Glycoengineering Therapeutic Proteins. Frontiers in Chemistry. https://doi.org/10.3389/fchem.2022.863118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.